Status: Not yet recruiting
A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
To evaluate the all-cause mortality rate at Day 28 in the YK-1169 group versus the ceftazidime-avibatan injection group in the mITT population.
Participants needed: 590
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Nanjing Yoko Biomedical Co., Ltd.Updated: Jun 8, 2026
Eligibility criteria
Obtain a signed, ethics committee-approved informed consent form prior to the st... [+5]
Study participants who received effective antibiotic therapy for more than 24 ho... [+19]